This is an interim data update with no new efficacy or regulatory decision — limited near-term trading catalyst. The next meaningful binary event is the PiNACLE data update in H2 2026. Current safety and translational data directionally positive but well within expectations for a CAR T therapy; no reason to reposition ahead of pivotal readout.
Price Chart
Executive Summary
Lyell Immunopharma presented updated Phase 1/2 safety and translational data for its CAR T-cell therapy ronde-cel at EHA 2026, including a 97% manufacturing success rate and no Grade ≥3 CRS in 108 patients with R/R LBCL, supporting potential for outpatient administration and durably differentiated responses. However, this is an interim data readout, not a pivotal regulatory event; the key catalyst is the PiNACLE trial data update expected H2 2026, with pivotal data and BLA submission not expected until mid-2027 and H2 2027, respectively.
Key Facts
- 108 patients with R/R LBCL treated with ronde-cel; 97% manufacturing success rate
- No Grade ≥3 CRS across 108 patients; Grade ≥3 ICANS in 8% (prophylaxis) vs 16% (no prophylaxis)
- Translational data: Cytotoxic T cells with Memory Potential (Tcmp) more abundant in durable responders (>12 months) vs progressive disease
- Durable complete responses >12 months observed even in patients with low CD19/CD20 antigen expression
- PiNACLE pivotal trial data update expected H2 2026; pivotal data mid-2027 with BLA submission H2 2027
Financial Impact
Pre-revenue clinical-stage biotech with $320M market cap; no financial data disclosed. Event is a data presentation, not a value-changing catalyst. Stock may see modest movement on perceived safety differentiation, but not transformative until pivotal data.
Risk Factors
- Clinical-stage biotech with no approved products; stock is pre-revenue and highly binary on trial outcomes
- PiNACLE data delay or negative efficacy/safety result would significantly impair valuation
- Historical reports on LYEL show negative average T+20 alpha (-4.17%) with only 33% win rate, suggesting model's reads have not captured market moves effectively for this name
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311241 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.26 (−40.22%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.26 (−27.88%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.26 (−25.56%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.26 (−31.41%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.26 (−24.78%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.26 (−22.64%) |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.26 (−59.06%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.26 (−61.16%) |
Apr 3, 2026 26w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.26 (−57.31%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.26 (−56.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access